According to the People's Daily, following the established work arrangements, from October 27th to 1030th, under the organization of the National Medical Insurance Bureau, 25 negotiation experts from medical insurance departments of various provinces conducted on-site negotiations and competitive bidding with relevant pharmaceutical companies, involving a total of 127 companies and 162 types of pharmaceuticals, including 117 types of pharmaceuticals outside the medical insurance list and 45 types of pharmaceuticals in the negotiation renewal list. The on-site negotiation work this year proceeded smoothly and stably, with overall results basically on par with previous years, meeting expectations. The newly expanded version of the medical insurance pharmaceutical catalog is expected to be released to the public at the end of November after "expansion," and will be officially implemented starting next year.

Officials from the Pharmaceutical Service Management Department of the National Medical Insurance Bureau stated that over the past six years, the agreement on newly added pharmaceuticals in medical insurance negotiations has generated nearly 500 billion yuan in sales within the agreement period, with medical insurance fund expenditures exceeding 340 billion yuan. The large-scale funds are mainly optimized and adjusted within the existing expenditure structure, without significantly increasing the financial burden on the public. This is mainly due to the preliminary establishment of a price adjustment mechanism for negotiated pharmaceuticals throughout the entire cycle, guiding a more fair and reasonable variety of agreement period prices through simple renewals and renegotiations. Simultaneously, by promoting the adoption of high-quality generic drugs and freeing up space to support innovative drugs, as well as measures such as strengthening regulation and reforming payment methods, the necessity, standardization, and rationality of pharmaceutical expenditure have significantly improved.

Since its establishment, the National Medical Insurance Bureau has shortened the catalog adjustment cycle from eight years to one year, with the number of varieties participating in negotiations each year expanding from 18 types in 2018 to over 100 types in recent years. Around 80% of new drugs can be included in the medical insurance catalog within two years after market launch.